바이오인포매틱스 시장 보고서 : 제품 및 서비스별, 용도별, 최종 이용 산업별, 지역별(2025-2033년)

The global bioinformatics market size reached USD 13.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 39.4 Billion by 2033, exhibiting a growth rate (CAGR) of 11.69% during 2025-2033. Rapid technological advancements, increasing genomic sequencing, surging demand for personalized medicine, data analytics growth, investment in research and development (R&D), expanding biological databases, and the rising focus on preventive care are some of the factors fostering the market growth.

Bioinformatics Market Analysis:

• Market Growth and Size: The bioinformatics market is witnessing substantial growth, propelled by its critical role in healthcare, agriculture, and environmental biotechnology. The expansion is reflected in the increasing market size, with projections indicating robust upward trends. This growth is fueled by the escalating demand for integrated data solutions, the burgeoning volume of biological data, and the widespread application of bioinformatics in various scientific domains. As bioinformatics market research underscores, this sector is becoming indispensable in deciphering complex biological datasets, driving innovations in personalized medicine, and enhancing our understanding of genetic and molecular foundations of diseases, thereby contributing significantly to the market's expansion and evolution.
• Major Market Drivers: The major market drivers include the escalating demand for nucleic acid and protein sequencing due to its cost-effectiveness, the integration of cloud computing, and the rise in microbial genome projects. Moreover, the increasing emphasis on data integration and management, widespread utilization in clinical diagnostics and precision medicine, expansion in the biopharmaceutical industry, and advancements in molecular biology, rising focus on immunogenomics, which is boosting the market growth. Apart from this, enhanced investment in bioinformatics startups and the surge in collaborative projects combining computational and biological research, collectively fuel the bioinformatics market growth, shaping a dynamic and rapidly evolving landscape.
• Technological Advancements: Technological advancements remain a pivotal force in the bioinformatics market, where ongoing innovation is key to addressing the complexity of biological data. Enhanced computational power, sophisticated algorithms, and machine learning (ML) applications are instrumental in advancing genomic and proteomic analyses. These technological strides are not only expanding the capabilities of bioinformatics tools but also are broadening their applicability across different sectors, including healthcare, agriculture, and environmental studies. Such advancements ensure that the bioinformatics field stays at the forefront of scientific research, facilitating rapid, accurate, and cost-effective analysis of biological data, which is essential for bioinformatics market trends.
• Industry Applications: The industry applications of bioinformatics span across healthcare, pharmaceuticals, agriculture, and environmental sciences. In healthcare, it's pivotal for developing personalized medicine and understanding genetic disorders. The pharmaceutical sector relies on bioinformatics for drug discovery, development, and biomarker identification. In agriculture, it aids in crop improvement and livestock management, while in environmental science, it's used for biodiversity conservation and monitoring ecosystem health.
• Key Market Trends: The bioinformatics market is characterized by the increasing use of artificial intelligence (AI) and ML in data analysis, the rise of personalized medicine requiring genomic data interpretation, the growing application in clinical diagnostics, and the expansion of cloud-based bioinformatics solutions. Moreover, the emphasis on precision agriculture leveraging genomic data, the surge in demand for biomarker discovery, and the integration of multi-omics data for comprehensive analysis are boosting the market growth.
• Geographical Trends: The bioinformatics market exhibits significant geographical disparities, with North America leading due to its advanced technological infrastructure, substantial investments in R&D, and strong presence of key industry players. The region's dominance is attributed to its rapid adoption of next-generation sequencing, high-throughput computing, and extensive use of bioinformatics in healthcare and agricultural biotechnology. Europe and Asia-Pacific are also notable contributors, with Europe benefiting from its robust research framework and Asia-Pacific witnessing fast-paced growth due to rising biotechnology ventures and increasing governmental support.
• Competitive Landscape: The competitive landscape of the bioinformatics market is intensely dynamic, featuring a mix of established companies and emerging startups. These entities compete on innovation, technological prowess, and strategic collaborations. Market leaders are continuously investing in R&D to introduce advanced solutions that cater to the growing complexity of biological data analysis. The sector is also witnessing a trend of mergers and acquisitions, as companies strive to enhance their offerings and expand their market reach.
• Challenges and Opportunities: The bioinformatics market is laden with challenges, including data complexity, the need for specialized skills, and issues related to data privacy and security. However, these challenges present unique opportunities for market growth and innovation. The increasing volume of biological data necessitates the development of more sophisticated bioinformatics tools, creating opportunities for advancements in AI and machine learning. Moreover, the growing demand for personalized medicine and the expanding application of bioinformatics across various industries offer vast prospects for the sector.

Bioinformatics Market Trends:

Technological advancements

Technological advancements are a cornerstone driver of the bioinformatics market, profoundly impacting its growth and capabilities. Innovations in computational algorithms, high-throughput sequencing technologies, and enhanced data processing software have revolutionized bioinformatics, enabling the analysis of vast biological datasets at unprecedented speeds and accuracy. These advancements facilitate complex genomic and proteomic analyses, leading to significant breakthroughs in understanding biological processes and disease mechanisms. They also enable the development of more sophisticated bioinformatics tools, improving the efficiency of research in genomics, transcriptomics, and various other omics fields, thereby accelerating scientific discoveries and their applications in personalized medicine, drug discovery, and other areas.

Increased genomic sequencing

The surge in genomic sequencing is a pivotal driver, fueled by the declining costs and improved accessibility of sequencing technologies. As sequencing becomes more widespread, it generates enormous volumes of data, necessitating advanced bioinformatics tools for effective data storage, management, and analysis. This exponential increase in genomic data is crucial for advancing personalized medicine, understanding genetic predispositions to diseases, and developing targeted therapies. The ability to sequence genomes rapidly and affordably has transformed biological research, enabling more comprehensive studies of human genetics, evolutionary biology, and microbial genomics, thus pushing the boundaries of bioinformatics to manage and decipher the complexity of these vast datasets.

Surging demand for personalized medicine

The demand for personalized medicine is significantly shaping the bioinformatics market, emphasizing the customization of healthcare, with medical decisions and treatments tailored to individual patients. This approach leverages genomic and clinical data to understand the molecular basis of diseases, predict the susceptibility to specific illnesses, and design personalized treatment regimens. Bioinformatics is integral to this process, providing the computational power to analyze and interpret the genetic variations and molecular patterns that influence health and disease. The resulting insights enable healthcare providers to make more informed decisions, offer targeted therapies, and improve patient outcomes, thereby driving the demand for sophisticated bioinformatics solutions in clinical settings.

Data analytics growth

The growth of data analytics in bioinformatics is transformative, offering powerful tools to decipher the complex data generated by genomic sequencing, gene expression studies, and other omic technologies. Bioinformatics is increasingly focusing on integrating data from multiple omics levels such as genomics, transcriptomics, proteomics, and metabolomics that provides a more comprehensive understanding of biological systems and disease mechanisms. Moreover, data analytics in bioinformatics heavily relies on machine learning (ML) and artificial intelligence (AI) techniques for predictive modeling, pattern recognition, and data interpretation.

Bioinformatics Industry Segmentation:

Breakup by Product and Service:

• Knowledge Management Tools
  • Generalized Knowledge Management Tools
  • Specialized Knowledge Management Tools
• Bioinformatics Platforms
  • Surgical Simulation Platforms
  • Sequence Analysis, Alignment and Manipulation Platforms
  • Structural and Functional Analysis Platforms
  • Others
• Bioinformatics Services
  • Data Analysis Services
  • Database Management Services
  • Others

Bioinformatics platforms dominates the market

The bioinformatics platforms segment is driven by the increasing complexity and volume of biological data, necessitating advanced platforms for data analysis, integration, and interpretation. The surge in genomic and proteomic studies, the expanding applications of next-generation sequencing, and the growing demand for integrative platforms for multidisciplinary research are key factors. These platforms are essential for translating vast biological data sets into comprehensible insights, facilitating advancements in personalized medicine, drug discovery, and genetic research.

The knowledge management tools segment is driven by the increasing need for organizations to harness the vast amounts of data generated and to transform this data into actionable insights. Factors such as the growing emphasis on decision-making based on data-driven insights, the escalating need for market intelligence, and the rising importance of enhancing operational efficiency are pivotal. Organizations are adopting these tools to improve innovation, streamline operations, and maintain competitive advantages by effectively managing, retrieving, and utilizing knowledge.

The bioinformatics services segment is driven by the increasing outsourcing of bioinformatics projects, the need for specialized expertise, and the growing demand for cost-effective and efficient data analysis solutions. Pharmaceutical and biotechnology companies, along with academic and research institutions, are leveraging these services to cope with the complexity of bioinformatics analyses, focus on core competencies, and accelerate the pace of research and development. The services segment is crucial for providing tailored solutions that address specific research requirements, ensuring high-quality analysis and interpretation of biological data.

Breakup by Application:

• Genomics
• Chemoinformatics and Drug Design
• Proteomics
• Transcriptomics
• Metabolomics
• Others

Genomics accounts for the majority of the market share

The genomics segment is driven by the increasing affordability of sequencing technologies, advancements in high-throughput sequencing methods, and a growing emphasis on personalized medicine. The expanding applications of genomics in understanding genetic variations, disease mechanisms, and therapeutic targets are catalyzing its adoption across various fields, including healthcare, agriculture, and biotechnology. This segment benefits significantly from continuous innovations in sequencing technologies, bioinformatics tools, and the integration of genomics with other omics disciplines, enhancing its impact on precision medicine, genetic research, and evolutionary biology.

The chemoinformatics and drug design segment is driven by the increasing demand for new therapeutic agents, the need for cost-effective drug development processes, and the integration of artificial intelligence and machine learning technologies. This segment leverages computational tools to understand drug-receptor interactions, predict pharmacokinetic and toxicological properties, and streamline the drug discovery pipeline. The growth of this segment is further propelled by the pharmaceutical industry's shift towards data-driven methodologies, the expansion of chemical databases, and the advancement of simulation and modeling techniques, all of which enhance the efficiency and effectiveness of drug discovery and development.

The proteomics segment is driven by the increasing advancements in mass spectrometry technologies, the growing demand for personalized medicine, and the expanding applications of proteomics in biomarker discovery and disease diagnostics. This segment benefits from the integration of proteomics data with other omics data, which enhances the understanding of cellular processes and disease mechanisms. The continuous improvement in proteomic workflows, the development of high-throughput and sensitive analytical techniques, and the increasing focus on systems biology are key factors contributing to the growth of this segment, enabling deeper insights into protein function, structure, and interactions.

The transcriptomics segment is driven by the increasing adoption of RNA sequencing technologies, the growing interest in understanding gene expression patterns, and the expanding application of transcriptomics in disease research and drug discovery. This segment is benefiting from advancements in sequencing technologies, computational biology, and the integration of transcriptomic data with genomics and proteomics, which enriches the understanding of gene regulation, cellular responses, and molecular mechanisms underlying various conditions.

The metabolomics segment is driven by the increasing application of metabolomics in clinical diagnostics, the growing emphasis on understanding metabolic pathways, and the advancements in analytical techniques like mass spectrometry. This segment is crucial for elucidating the functional state of biological systems, providing insights into the phenotypic changes caused by genetic or environmental factors. The integration of metabolomics with other omics technologies, the growing demand for biomarker discovery, and the expanding applications in personalized medicine and nutritional research are key factors propelling the growth of this segment, offering comprehensive insights into the metabolic processes and their implications in health and disease.

The others segment in bioinformatics is driven by the increasing demand for integrated omics approaches, the expansion of applications in areas such as epigenomics, pharmacogenomics, and environmental genomics, and the growing need for advanced computational tools to analyze complex datasets. This segment encompasses a variety of specialized fields that leverage bioinformatics technologies to explore the biological data beyond conventional omics studies.

Breakup by End-Use Sector:

• Medical Biotechnology
• Academics
• Animal Biotechnology
• Agricultural Biotechnology
• Environmental Biotechnology
• Forensic Biotechnology
• Others

Medical biotechnology accounts for the majority of the market share

The medical biotechnology segment is driven by the increasing demand for personalized medicine, advancements in genetic engineering, and the growing prevalence of chronic diseases. Innovations in gene therapy, stem cell technology, and regenerative medicine are revolutionizing treatments, making them more effective and tailored to individual genetic profiles. The surge in biopharmaceuticals, including vaccines and therapeutic proteins, and the emphasis on early disease detection and prevention are key factors propelling this segment forward. These developments are enhancing patient outcomes, reducing healthcare costs, and leading to the discovery of novel therapeutics, thereby fueling the growth of medical biotechnology.

The academics segment is driven by the increasing collaboration between research institutions and the biotechnology industry, the growing focus on genomic and proteomic research, and the rising demand for biotechnology education. Enhanced funding for research projects, the integration of advanced technologies in academic curricula, and the emphasis on developing innovative biotechnological applications are pivotal.

The animal biotechnology segment is driven by the increasing investment in veterinary research, the demand for enhanced animal health and productivity, and the development of genetically modified animals. Breakthroughs in animal genetics, vaccine development, and reproductive technologies are instrumental in improving animal breeding, disease resistance, and protein production. This segment's growth is further supported by the ethical production of transgenic animals, advancements in cloning and stem cell research, and the application of biotechnological methods in wildlife conservation, thus offering significant contributions to veterinary medicine and livestock management.

The agricultural biotechnology segment is driven by the increasing global demand for food, the need for pest and disease resistance, and the urgency to adapt to climate change. Genetic modifications in crops for improved yield, quality, and nutritional value, along with advancements in biopesticides and biofertilizers, are crucial developments. This segment leverages biotechnological tools for sustainable farming practices, enhancing crop resilience to environmental stresses, and reducing agricultural inputs, which are vital for food security and agricultural sustainability, thus playing a key role in the global agricultural landscape.

The environmental biotechnology segment is driven by the increasing need for waste management, pollution reduction, and sustainable environmental practices. The application of microbial systems for bioremediation, the development of bioenergy sources, and the use of biotechnological processes for water treatment are pivotal. This segment focuses on harnessing biological systems for the detoxification of contaminated environments, the recycling of waste materials, and the production of green energy, thereby contributing significantly to environmental sustainability and the conservation of natural resources.

The forensic biotechnology segment is driven by the increasing demand for accurate and speedy forensic investigations and advancements in molecular diagnostics. The application of biotechnological tools in crime scene analysis, the development of sophisticated forensic databases, and the enhancement of legal frameworks are key factors. This segment benefits from the precision and reliability of biotechnological methods in forensic science, providing crucial evidence in criminal cases, identifying victims of disasters, and contributing to the justice system, thereby playing a vital role in law enforcement and forensic investigations.

The others segment, which includes industrial, marine, and food biotechnology, is driven by the diverse applications of biotechnological processes in various sectors. The development of bio-based chemicals, the use of enzymes in industrial processes, and the advancement of marine biotechnology for new drug discovery are key factors.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America leads the market, accounting for the largest Bioinformatics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others);Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The North America bioinformatics market is driven by the increasing investment in biotechnology and pharmaceutical research, the presence of a robust technological infrastructure, and significant governmental and private funding for genomics research. The region benefits from a well-established healthcare system, a high rate of adoption of advanced technologies, and the presence of leading bioinformatics companies, which collectively fuel innovation and market expansion.

The Europe bioinformatics market is driven by the increasing focus on precision medicine, strong governmental support for research in genomics, and collaborations between academia and the biotech industry. The region's advanced healthcare infrastructure, coupled with high healthcare expenditure, facilitates the adoption of bioinformatics tools, supporting the market's growth and the development of new applications.

The Asia Pacific bioinformatics market is driven by the rapidly growing biotechnology sector, increasing government initiatives in genomics research, and rising investments in healthcare technology. The region's growing emphasis on personalized medicine and the expansion of the pharmaceutical and agriculture sectors contribute significantly to the adoption of bioinformatics, making it a fast-evolving market.

The Latin America bioinformatics market is driven by the increasing healthcare expenditure, growing biotech and pharmaceutical sectors, and rising awareness about the potential of genomics research. Although in the nascent stage, the market benefits from the gradual adoption of advanced technologies and the improving healthcare infrastructure, which are pivotal for the region's bioinformatics advancements.

The Middle East and Africa bioinformatics market is driven by the growing demand for personalized healthcare, increasing investment in healthcare infrastructure, and the rising prevalence of genetic disorders. The market is also benefiting from the expanding research in genomics and the increasing collaboration between regional and international research institutions, fostering a gradual yet promising growth in the bioinformatics landscape.

Leading Key Players in the Bioinformatics Industry:

In the bioinformatics market, key players are actively engaged in a range of strategic activities to bolster their market position and respond to the rapidly evolving technological landscape. They are heavily investing in research and development (R&D) to innovate and enhance bioinformatics tools, software, and services, ensuring they can handle the increasing complexity and volume of biological data. Collaborations and partnerships are a cornerstone strategy, as companies join forces with academic institutions, research labs, and other firms to combine expertise, share resources, and co-develop advanced solutions that cater to the specific needs of the scientific community. Additionally, these players are focusing on expanding their product portfolios through mergers and acquisitions, enabling them to offer more comprehensive solutions and gain a competitive edge. They are also intensifying their efforts in customer training and support, ensuring users can maximize the benefits of their bioinformatics solutions, thereby driving market growth and innovation.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• ABM Industries
• Agilent Technologies
• Biomax Informatics
• Data4Cure Inc.
• Dnastar Inc.
• Illumina Inc.
• Life Technologies
• PerkinElmer Inc.
• Qiagen N.V.
• Quest Diagnostics
• Sophia Genetics SA
• Thermo Fisher Scientific Inc.
• Waters Corp
• WuXi Nextcode Genomics

Key Questions Answered in This Report

• 1.What is the global bioinformatics market growth?
• 2.What are the global bioinformatics market drivers?
• 3.What are the key industry trends in the global bioinformatics market?
• 4.What is the impact of COVID-19 on the global bioinformatics market?
• 5.What is the global bioinformatics market breakup by product and service?
• 6.What are the major regions in the global bioinformatics market?
• 7.Who are the key companies/players in the global bioinformatics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Bioinformatics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product and Service

• 6.1 Knowledge Management Tools
  • 6.1.1 Market Trends
  • 6.1.2 Major Types
    • 6.1.2.1 Generalized Knowledge Management Tools
    • 6.1.2.2 Specialized Knowledge Management Tools
  • 6.1.3 Market Forecast
• 6.2 Bioinformatics Platforms
  • 6.2.1 Market Trends
  • 6.2.2 Major Types
    • 6.2.2.1 Surgical Simulation Platforms
    • 6.2.2.2 Sequence Analysis, Alignment and Manipulation Platforms
    • 6.2.2.3 Structural and Functional Analysis Platforms
    • 6.2.2.4 Others
  • 6.2.3 Market Forecast
• 6.3 Bioinformatics Services
  • 6.3.1 Market Trends
  • 6.3.2 Major Types
    • 6.3.2.1 Data Analysis Services
    • 6.3.2.2 Database Management Services
    • 6.3.2.3 Others
  • 6.3.3 Market Forecast

7 Market Breakup by Application

• 7.1 Genomics
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Chemoinformatics and Drug Design
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Proteomics
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Transcriptomics
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Metabolomics
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Other Applications
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by End-Use Sector

• 8.1 Medical Biotechnology
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Academics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Animal Biotechnology
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Agricultural Biotechnology
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Environmental Biotechnology
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Forensic Biotechnology
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast
• 8.7 Others
  • 8.7.1 Market Trends
  • 8.7.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 ABM Industries
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 Agilent Technologies
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
  • 13.3.3 Biomax Informatics
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
  • 13.3.4 Data4cure Inc.
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
  • 13.3.5 Dnastar Inc.
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
  • 13.3.6 Illumina Inc.
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
    • 13.3.6.4 SWOT Analysis
  • 13.3.7 Life Technologies
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
  • 13.3.8 Perkinelmer Inc.
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis
  • 13.3.9 Qiagen N.V.
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
  • 13.3.10 Quest Diagnostics
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financials
    • 13.3.10.4 SWOT Analysis
  • 13.3.11 Sophia Genetics SA
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio
  • 13.3.12 Thermo Fisher Scientific Inc.
    • 13.3.12.1 Company Overview
    • 13.3.12.2 Product Portfolio
    • 13.3.12.3 Financials
    • 13.3.12.4 SWOT Analysis
  • 13.3.13 Waters Corporation
    • 13.3.13.1 Company Overview
    • 13.3.13.2 Product Portfolio
    • 13.3.13.3 Financials
    • 13.3.13.4 SWOT Analysis
  • 13.3.14 WuXi Nextcode Genomics
    • 13.3.14.1 Company Overview
    • 13.3.14.2 Product Portfolio